Pitcairn’s Blueprint Medicines BPMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-4,744
| Closed | -$608K | – | 637 |
|
|
2025
Q2 | $608K | Sell |
4,744
-6,303
| -57% | -$655K | 0.04% | 366 |
|
|
2025
Q1 | $978K | Buy |
11,047
+439
| +4% | +$42.8K | 0.06% | 278 |
|
|
2024
Q4 | $925K | Buy |
10,608
+293
| +3% | +$26.8K | 0.05% | 277 |
|
|
2024
Q3 | $954K | Buy |
10,315
+5,783
| +128% | +$574K | 0.06% | 282 |
|
|
2024
Q2 | $488K | Buy |
4,532
+298
| +7% | +$29.8K | 0.03% | 449 |
|
|
2024
Q1 | $402K | Sell |
4,234
-654
| -13% | -$56.1K | 0.03% | 490 |
|
|
2023
Q4 | $451K | Buy |
4,888
+45
| +0.9% | +$2.92K | 0.03% | 429 |
|
|
2023
Q3 | $243K | Buy |
4,843
+277
| +6% | +$14.8K | 0.02% | 562 |
|
|
2023
Q2 | $289K | Sell |
4,566
-296
| -6% | -$16.1K | 0.02% | 521 |
|
|
2023
Q1 | $219K | Buy |
+4,862
| New | +$219K | 0.02% | 565 |
|
|
2022
Q4 | – | Sell |
-3,375
| Closed | -$222K | – | 588 |
|
|
2022
Q3 | $222K | Buy |
+3,375
| New | +$217K | 0.02% | 528 |
|
|
2022
Q2 | – | Sell |
-3,446
| Closed | -$220K | – | 580 |
|
|
2022
Q1 | $220K | Sell |
3,446
-743
| -18% | -$53.3K | 0.02% | 579 |
|
|
2021
Q4 | $449K | Sell |
4,189
-1,257
| -23% | -$131K | 0.03% | 404 |
|
|
2021
Q3 | $559K | Sell |
5,446
-1,380
| -20% | -$129K | 0.04% | 313 |
|
|
2021
Q2 | $600K | Buy |
6,826
+2,831
| +71% | +$259K | 0.04% | 286 |
|
|
2021
Q1 | $388K | Buy |
3,995
+292
| +8% | +$29.2K | 0.03% | 406 |
|
|
2020
Q4 | $415K | Buy |
3,703
+182
| +5% | +$19.2K | 0.03% | 340 |
|
|
2020
Q3 | $326K | Sell |
3,521
-1,932
| -35% | -$149K | 0.03% | 342 |
|
|
2020
Q2 | $425K | Buy |
+5,453
| New | +$369K | 0.04% | 258 |
|
Other funds holding BPMC
IA
HNB
Pitcairn's BPMC Position: Q3 2025 in Review
Pitcairn sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 4,744 shares — an estimated $608K sold.
Pitcairn first reported a position in BPMC in Q2 2020 and held it in 19 quarters. The position peaked at $978K in Q1 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.
- Pitcairn reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
- Pitcairn sold 4,744 Blueprint Medicines shares in Q3 2025, an estimated $608K.
- Pitcairn first reported a position in Blueprint Medicines in Q2 2020 and held it in 19 quarters.
- Pitcairn's Blueprint Medicines position peaked at $978K in Q1 2025.
- 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.
Based on Pitcairn's 13F filing for Q3 2025, filed 12 Nov 2025.